Aquestive stock: buy or sell?

AQST stock price: $4.10 -0.97% At close on January 17th, 2020

Updated on:
January 17th, 2020

0

After sliding a chilling -5.31% on Jan/16, Aquestive Therapeutics closed yesterday at $4.10 and depreciated a bad -0.97%.

Should I buy Aquestive stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. That's why is so important to choose your own trading strategy that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

Currently, Aquestive Therapeutics stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Aquestive Therapeutics stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we collected 4 ratings published for AQST stock in the last month.

The general sentiment of these ratings is bullish for AQST stock, with 4 positive ratings.
Is AQST a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-9-30Wedbushn/aBuy
2019-3-22Wedbushn/aBuy
2019-3-15BMO Capital MarketsIn-LineOutperform
2019-2-20Lake Street Capitaln/aBuy

Aquestive stock analysis

Daily outlook

After sliding a chilling -5.31% on Jan/16, Aquestive Therapeutics closed yesterday at $4.10 and depreciated a bad -0.97%.

After sliding a chilling -5.31% on Jan/16, Aquestive Therapeutics closed yesterday at $4.10 and depreciated a bad -0.97%. Since price and SMA200d lines crossed down on Monday, AQST fell $-2.51 per share (-37.97%). Since last January 9th when SMA100d and SMA200d crossed up, AQST price slipped $-2.29 per share (-35.84%).

AQST stock chart (daily)

Weekly outlook

After climbing for 4 weeks, this week Aquestive Therapeutics plunged a chilling -37.97%, closing at $4.10. Last week AQST boosted an amazing 11.35% in just one week.

Aquestive Therapeutics finally dropped through the support and now is sliding further into fresh lows looking for new supports. This week, Aquestive Therapeutics stock undercut the significant level of the 40-weeks moving average. Stocks under the 40-weeks moving average line are usually not recommended for average traders. Since late December 2019 when SMA20w and SMA40w crossed up, AQST price slipped $-1.44 per share (-25.99%).

AQST stock chart (weekly)

Aquestive stock price history

Aquestive stock went public on July 25th, 2018 with a price of $15.101. Since then, AQST stock sliced a -72.80%, with a yearly average of -72.80%.

1: Adjusted price after possible price splits or reverse-splits.

Aquestive stock historical price chart

AQST stock reached 52-week highs on December at $10.00, and all-time highs 2018-09-13 with a price of 20.7.

Aquestive stock price target is $25.50

Nobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We detected 2 price targets for Aquestive stock released in the last 30 days:
AQST stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-3-22WedbushSet Price Targetn/a$30.00-
2019-3-15BMO Capital MarketsLowers Targetn/a$21.00-
(in average)$0.00$25.500.0%
Moving in a range from $30.00 and $21.00, the price prediction for AQST stock is $25.50. In average, analysts' outlook on AQST price forecast is stable from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

Aquestive failed analysts on March when it published an Earnings per Share (EPS) of $-0.56 when the market consensus was $-0.91.
AQST earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
0000-Q2-n/an/an/a
2017-Q1-n/an/an/a
2017-Q2-n/an/an/a
2017-Q4-n/an/an/a
2018-Q1-n/an/an/a
2018-Q22018-09-04n/a-1.9n/a
2018-Q32018-11-06-0.49-0.49n/a
2018-Q42019-03-14-0.91-0.56n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

Compared to 2017, last anual revenues report draw a slightly good move of 0.77% to $67.43 M dollars. When comparing 2018 vs 2017, nonetheless, profit margin (that is, the net income divided by revenues) collapsed a -77.66% to -91.02%.

AQST annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2016$52 M-$-9.60 M-18.5%-
2017$67 M29.22%$-8.94 M-13.4%-6.86%
2018$67 M0.77%$-61.38 M-91.0%586.30%

Quarterly financial results

Aquestive Therapeutics reported $16.82 million in sales for 2018-Q4, a 26.81% improvement compared to previous quarter. Reported quarter earnings marked $-13.94 M with a profit margin of -82.88%. Profit margin climbed a 30.47% compared to previous quarter when profit margin was -113.35%. When comparing sales to same quarter last year, Aquestive sales marked a super good increase and boosted a 37.96%.
AQST quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$16 M-$-1.46 M-8.9%-
2017-Q2$11 M-32.21%$-5.90 M-52.9%304.74%
2017-Q4$12 M9.45%$-10.04 M-82.3%70.26%
2018-Q1$23 M91.97%$4.10 M17.5%-140.83%
2018-Q2$14 M-40.51%$-36.49 M-262.0%-990.29%
2018-Q3$13 M-4.75%$-15.04 M-113.3%-58.79%
2018-Q4$17 M26.81%$-13.94 M-82.9%-7.27%

Aquestive ownership

When you are planning to invest in shares of a stock, it's always worth to review its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Aquestive Therapeutics, 14.88% of all outstanding shares are owned by its staff.

In case of Aquestive stock, 47.52% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for AQST stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Aquestive Therapeutics:

AQST
Market cap$102.7 M
Total shares25.0 M
Float shares19.1 M
  - Institutional holdings (%)47.5%
  - Insider holdings (%)14.9%
Shares in short selling0.0%

Aquestive summary

Friday, January 17th, 2020
Open$4.14
Close$4.10
Day range$4.06 - $4.30
Previous close$4.14
Session gain-0.97%
Average true range$0.58
50d mov avg$6.16
100d mov avg$4.81
200d mov avg$4.70
Daily patternlt06c
Weekly pattern lt01c

Aquestive performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We compared Aquestive against in the following table:
Stock3m6m12m
AQSTAquestive Therape...22.39%-0.24%-40.75%

Aquestive competitors

Unfortunately, we could not find any public company that could be defined as Aquestive Therapeutics competitor. This doesn't mean Aquestive Therapeutics does not have any competitor in the market, it's just we could not detected it.